.

Ultragenyx Pharmaceutical reported $-157860000 in Pre-Tax Profit for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Acadia Pharmaceuticals ACAD:US $ -33.57M 79M
Agios Pharmaceuticals AGIO:US $ -91.81M 2.97M
Alnylam Pharmaceuticals ALNY:US $ -274.67M 35.32M
Aptinyx Inc APTX:US $ -17667000 2.16M
Biomarin Pharmaceutical BMRN:US $ 34.85M 8.66M
Bluebird Bio BLUE:US $ -100.14M 22.01M
Epizyme EPZM:US $ -35.74M 19.73M
Esperion Therapeutics ESPR:US $ -66324000 9.59M
Insmed INSM:US $ -95144000 908K
IONIS PHARMACEUT IONS:US $ -103M 39M
Karyopharm Therapeutics KPTI:US $ -48941000 7.67M
Kyowa Hakko Kirin 4151:JP Y 24763M 6047M
Macrogenics MGNX:US $ -41.3M 25.14M
Mirati Therapeutics MRTX:US $ -176.44M 11.94M
Neurocrine Biosciences NBIX:US $ -23.3M 44.7M
Ptc Therapeutics PTCT:US $ -148.7M 26.8M
Sarepta Therapeutics SRPT:US $ -228.09M 123.95M
Ultragenyx Pharmaceutical RARE:US $ -157.86M 6.1M
Vital Therapies VTL:US $ -21.9M 1.09M
Xoma XOMA:US $ -4.67M 2.39M